Thanks David, and afternoon. thanks us joining everybody for this
stroke of that the our execute support It continued on appreciate our we reporting the calls. of implemented our of fact period as digit the well of growth. by prevent which treatment established plan and laid double to increased of the Let first as marks continued strategies is increased over disease, new quarter XXX% since year, the designed progress is the sales carotid $X like America. on new the our Latin fifth last to is due me XXXX, over that we fourth we the markets lead quarter. conference for Asia product as our quarter investors same we into saying our of EPS, and artery This to continue consecutive start I first an previous Sales Italy, result strategy, in during markets out company's expansion are our have CGuard and million XX% for clear in Germany working in in excess time
publications. to significant industry gain continues conferences features at be CGuard top to Additionally, review and the visibility in leading continues pre
thought a in of System Conference prevention recently As talks separate an ICCA and Embolic on the Prevention five the at example, the panel features world are all Warsaw, in LINK stroke. CGuard that was discussion Leipzig, two consisted and was CGuard disease Poland, Stroke Europe treatment over of held of conferences the LINK focused Interventional from also Conference in at ICCA in two transmissions Stroke XXXX Both and and in live that premier stroke. case the clinical targeting prominently artery specialties featured carotid the Germany. held treat leaders
money with involving and with to presentations, conference independent program are even and their own CGuard. approaching physicians unsolicited spending They to purchasing our involved trials additions be to In and CGuard. time us are product run
year. and being standard have in at Center by Circulation by conducted data buildup DW be in trend that carotid enrollment Novosibirsk, for Institute carotid of patient a The on is CGuard the CGuard with additional safer events alternative Pathology current that to procedure. vascular MRI stroke, investigator-initiated the the as appears standard stenting at is for treated this and market carotid conventional EPS to effective track vascular to compare care consistent the the this, within would carotid suggesting trial trial patients a for this conventional risk may versus lower analyses endarterectomy; the trial carotid are continuing the comparing offer and which Acculink disease. Carotid To end the endarterectomy. risk RX in CGuard Karpenko, the risk is factors example, for complete stent the an safe similar As clinical of the CGuard. of objective versus The This high procedure are surgery continues evaluated data for at of of artery suggest patients Scientific Russia. treating artery CGuard surgical currently carotid could market-leading of carotid which embolic XX stent The a hybrid using of professor when Stent significantly therapy, are superiority is surgeon explain endarterectomy continuing medical trial Andrei surgical expand led of for EPS. by Abbott's patients with to addressable date further enrolled enrollment in versus to been
a carotid result, associated has that been many embolization stents. are As still artery to of endarterectomy the using stenting risk surgeons carotid conventional performing stroke or reduce post-surgical carotid with
procedural advantages be CGuard the device, options could market for will to safety acceptance disease we to to well their post stenting they believe However, carotid for now reevaluate some and believe and are carotid compelled when $XXX device a over approximately from We the artery of with billion. CGuard. broaden addressable the surgeons reported switching understand our $X million expansion such the treating
us and to Caribbean commercial this attract of distributor. our regulatory and strategy valid not illustrates as sales quick following of quickly CGuard approvals as immediately enabling marketing up connections we leaders with the of line Greece, well commercialization clearance. advisory and strong scientific artery sign regulatory with This to announced coverage those with particular excellent experience knowledgeable treat a secure new our first distributors opinion but carotid countries, our Vietnam. we these Just did in with devices; particularly approval or to strategy, implement follows our In and and disease bodies strengthen appropriate members complement to to but our markets. regulatory country an adding in only board CGuard and already ability continue and we distributors region. due a we launch key in as those leading from receipt those in sales our South begin the and India, last and in commercial new of endovascular In Scientific They and Using who an Much direction to represent team members America, ability of Europe, from and The is The and endovascular in States, leaders experts also are announced programs. leading This product United quickly. license field. commercialization product provide Board physicians, new rather clinics institutions partners clinical to Thus medical announced the India in centers, the to guidance knowledgeable support example was distribution week, the Israel. Latin formed the secured Vietnam with and and only get our InspireMD disorders. endovascular not Board to import Advisory and Korea. development approval, we diseases for reimbursement research opinion Peru, in researchers research Russia of previously for regulatory hospitals,
honored leading about our world around incredibly are team. the these are from joining excited physicians We that
evaluate Given traction the the States. we world, our to the around United we restarting are in efforts gaining continue
trial obtain FDA be investigational an Both plan, we or on positive previous noted regarding meeting clinical by design. must preclinical call, device FDA as IDE. had of exemption our and testing proposed a As met proposed last with these order the year to accepted as our well a in
evaluate low and we opportunities, focus And is technology wisely successful that entering pipeline product commit have we low a approach to additional know, differentiator. relatively significant that unmet will and expense synergistic, United the you internal are strategy, needs States we thus market ensure takes advantage money. address a thus to on need Further, through time risk provides competitive as US can our see and micronet conclusion. leverage a once development As it and this we and but a proprietary we also products and mesh to
commercial expand the of to and extensions distribution us Lastly, Asia distribution building channels exploring our our leverage we a product Europe., capital other Latin networks foundation and America. of sales network, we given continued we're may synergistic operations business the opportunities and further also established across that have and strengthening allow our and to are structure, variety and
discussed felt last I revenue recapitalizing starting the attention the In up base to process and our structure,. turn As the and the to see to announced the on of we time year, the capital we're given we November of structure. cleaning call, was improvements our business last it begin to growth, company the capital in plan our
this completed convert company. most that prevented company overhang well shareholders This end, investors Towards allowed existing our between preferred invest field was of we no preferential playing a more shareholders, in of shares also investors has the level wish a major health problematic the only worry future the removed making strategic and to attractive will of the and has general. this new critical provisions. from to most balance to not as longer potential terms a as eliminate investors provides fundamental to raises believe eliminates but that to stock ensuring the the the in sheet, as who have strengthened it and more care about funds and attracting preferential new us that story We series us in also capital
consequences and outstanding we Since it of are the as we organization will to footing shares I ensuring prove more InspireMD helm today, shares rebuilding joined Directors suffer the made of system. for the believe Board make all commercially So meaningful XXXX, million. them, to the in the that believe taking taken and these and steps the events now of mid-XXXX believed important did and catastrophic difference are for both success We products clinically. conversion I is CEO the were in X.X I because ultimately much potential of fundamentally we've from operational goal vascular assuming as from necessary can all this of now given beneficial available of the shareholders in solid that on patients When experiencing. preferred embolic technology have with substantial patients benefit progress the are in I a of the
proceeds the $X.X capital million closed in in raise, and in Importantly, April. subsequently added which cash our we quarter recent over ended million $X.X with another net from
for Florida We rate management. our in on now down burn focus from approximately the cash Our have growth million is period greater same was $X.X to the continued strategy. flexibility This our much result on a a execute of XXXX.
quarter Once and from Craig? appreciate to over with year. we're strong of last will the the shareholders. I after XXXX questions million since first support And achieving the the presents the financials. off look Craig your million a $X and strategy. growth year new in answering the a same expect we forward to patience for and X XXX% start great our in Including first implemented quarter again, We sales we period be CGuard
